Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI).

https://www.marinomed.com/en/data-protection-declaration
https://www.marinomed.com/en/legal-notice

Biotechnology

Health Care

Therapeutics

Marinomed Biotech AG

Marinomed Biotech AG's headquarters in Korneuburg, Austria

Marinomed Biotech AG

Org chart

Teams

Offices

Similar companies